TABLE 2

Demographic Data

MethodParticipantSexIndicationAge (y)Body mass indexAdministered activity (MBq)Injection time*Whole-body imaging time*Percentage estimated effective dose increaseImaging findings according to indication
CyclotronC1FBilateral thyroid nodule4528.0296.85:036:34Hypothyroidism
C2FHyperthyroidism, Graves disease4931.3351.56:317:291.04Graves disease
C3FMultinodular goiter7725.0291.45:487:321.20Subclinical hyperthyroidism
C4FHypothyroidism3419.4351.05:366:340.94Thyroiditis
C5FHyperthyroidism2817.2353.36:497:521.15Thyroiditis, goiter?
C6MNodules6022.7329.94:546:131.54Multinodular goiter
C7FGraves disease1925.5270.76:077:041.75Graves disease
C8MHyperthyroidism de novo6527.6330.24:406:031.60Thyroiditis
C9FHyperthyroidism4735.8308.66:417:321.98Graves disease
C10FThyroiditis or hyperthyroidism3234.1347.75:356:131.76Thyroiditis
C11MHyperthyroidism3622.6348.47:039:001.93Graves disease
GeneratorG1FNodule3439.8345.6NANANANonfunctional nodule formation
G2MHyperthyroidism6621.1346.5NANANAThyroiditis
G3FGoiter, Graves disease3124.2341.7NANANASubclinical hyperthyroidism, suspected thyroid nodule
G4FNodules4719.7340.0NANANASubclinical hyperthyroidism, hyperfunctional nodules
G5FHyperthyroidism2818.3349.5NANANAGraves disease
G6FNodules5016.2334.6NANANAMultinodular goiter
G7MNodule5927.2345.1NANANANonfunctional thyroid nodule
G8FHyperthyroidism3535.3336.0NANANAGraves disease, suspected nonfunctional nodule
  • * Hours after EOB.

  • NA = not applicable.